查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953958

下一代糖尿病治療和藥物傳輸市場－全球產業規模、佔有率、趨勢、機會及預測（按產品類型、適應症、最終用戶、地區和競爭格局分類，2021-2031年）

Next Generation Diabetes Therapy and Drug Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Indication, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球下一代糖尿病治療和藥物輸送市場預計將從 2025 年的 238.6 億美元成長到 2031 年的 363.1 億美元，複合年成長率為 7.25%。

此細分市場包括新型胰島素類似物和Glucagon-Like Peptide-1受體促效劑等先進藥物，並結合貼片幫浦和連續血糖監測儀等自動化給藥技術，以增強血糖控制。推動此市場發展的關鍵因素包括：迫切需要能夠提高患者依從性的非侵入性治療方法，以及全球代謝性疾病負擔的快速惡化。根據國際糖尿病聯盟（IDF）2024年報告，全球約有5.89億成年人患有糖尿病，這顯著增加了對這些先進治療方法的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 238.6億美元
市場規模：2031年 363.1億美元
複合年成長率：2026-2031年 7.25%
成長最快的細分市場 CGM系統
最大的市場 北美洲

然而，這些先進生物製藥和醫療設備的高昂成本是市場推廣的一大障礙，這不僅限制了注重成本地區的病患取得途徑，也造成了龐大的醫保報銷難題。這種經濟障礙，加上複雜組合產品的嚴格監管核准標準，共同限制了這些治療方法惠及更廣泛患者群體的速度。

市場促進因素

全球糖尿病和肥胖相關併發症的日益流行，正成為加速整合式醫療服務體系和先進藥物干預措施應用的重要催化劑。代謝性疾病的激增促使患者更加依賴新一代治療方法，尤其是雙重GIP和GLP-1受體促效劑，與傳統胰島素療法相比，這些藥物在血糖控制和體重管理方面表現更佳。疾病發生率的上升與這些新型生物製藥的商業性成功之間存在直接關聯，因為醫療服務提供者優先考慮能夠同時控制血糖和減輕體重的治療方法。禮來公司在2024年第二季財報中指出，其治療藥物Munjaro的全球銷售額僅在第二季度就飆升至30.9億美元，這反映了市場對此類藥物的旺盛需求，也凸顯了疾病負擔在推動創新療法應用方面所發揮的重要作用。

此外，封閉回路型和自動化胰島素輸注系統的快速發展，滿足了患者對持續、微創監測解決方案的需求，從而推動了市場成長。將即時數據分析與自動化輸注結合的技術，能夠減輕認知負擔，並降低手動注射相關的低血糖風險。這些先進設備的廣泛應用對於應對更廣泛的代謝危機至關重要。值得注意的是，根據世界衛生組織 (WHO) 2024 年的一份報告，肥胖症影響著全球超過 10 億人，因此對擴充性的治療方法方案有著巨大的需求。正因如此，製造商們預計這些產品將被廣泛應用。根據雅培公司 2024 年第三季的財務業績，FreeStyle Libre 系統的全球銷售額達到 16 億美元，主要得益於其能夠促進個人化照護。

市場挑戰

先進糖尿病生技藥品和醫療設備的高成本是限制全球下一代糖尿病治療和藥物傳輸市場成長的一大障礙。儘管自動化輸注系統和新型胰島素類似物能夠提供更優的血糖控制，但其高昂的價格使得全球大部分人口，特別是那些自費醫療普遍存在的低度開發地區，難以負擔。這種經濟差距將目標市場主要限制在富裕人群和擁有廣泛醫療保險的人群，使得製造商難以在已開發市場之外拓展業務。

此外，這種經濟負擔導致保險公司和醫療支付方的審查力度加大，從而製定了嚴格的報銷標準，並減緩了市場滲透率。高昂的現有醫療成本使得支付方不願意核准昂貴的新治療方法。根據國際糖尿病聯盟（IDF）估計，到2024年，全球與糖尿病相關的醫療成本將達到1.15兆美元。這種嚴峻的財務壓力迫使醫療系統優先考慮成本控制，從而限制了高價值治療技術的廣泛資金籌措和資金投入。

市場趨勢

市場正經歷著向小型化、無導管、穿戴式貼片幫浦技術的明顯轉變，從根本上改變了胰島素的輸送機制。與傳統的依賴導管的持續釋放胰島素幫浦不同，這些隱藏、防水的設備可直接貼附於皮膚上，為患者提供更大的自由度，並最大限度地減少與可見醫療設備相關的社會污名。這種特殊的外形設計尤其吸引年輕人和生活方式活躍的人群，他們先前由於導管式設備的物理限制而避免使用胰島素幫浦治療。這一趨勢的商業性成功在Insulet公司2024年第三季的財務業績中得到了充分體現，該公司報告的營收為5.439億美元，這主要得益於市場對其無導管自動胰島素輸送平台的強勁需求。

同時，開放式糖尿病生態系統和設備互通性正在迅速發展，實現了不同製造商組件的無縫整合。這一趨勢正在打破專有單一品牌系統的局面，使患者能夠將自己偏好的胰島素幫浦與不同的連續血糖監測感測器配對，從而創造出個人化的管理方案。這種柔軟性改善了用戶體驗，並透過消除傳統上限制患者選擇的硬體相容性障礙，促進了自動化治療的更廣泛應用。為了體現這種互通性策略帶來的財務影響，Tandem Diabetes Care 在 2024 年第三季財報中公佈了 2.435 億美元的全球銷售額，這主要得益於其胰島素幫浦平台和多種感測器技術的整合。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球下一代糖尿病治療與藥物傳遞市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（吸入式胰島素、口服胰島素、胰島素貼片、動態血糖監測系統、人工胰臟）
    • 依適應症（1 型糖尿病、2 型糖尿病）
    • 依最終使用者（診斷/診所、加護病房(ICU)、家庭醫療保健）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美下一代糖尿病療法和藥物傳輸市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲下一代糖尿病療法和藥物傳輸市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區下一代糖尿病療法和藥物傳遞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲下一代糖尿病療法和藥物傳輸市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲新一代糖尿病療法與藥物傳遞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

13. 全球下一代糖尿病治療與藥物輸送市場：SWOT 分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories
  • Dexcom Inc.
  • Eli Lilly and Company
  • Enteris BioPharma Inc.
  • GlySens Incorporated
  • MannKind Corporation
  • Medtronic plc
  • Sanofi SA
  • Senseonics, Holdings

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20093

The Global Next Generation Diabetes Therapy and Drug Delivery Market is projected to expand from USD 23.86 Billion in 2025 to USD 36.31 Billion by 2031, reflecting a compound annual growth rate of 7.25%. This sector encompasses advanced pharmacological agents, including novel insulin analogs and glucagon-like peptide-1 receptor agonists, integrated with automated administration technologies such as patch pumps and continuous glucose monitors to enhance glycemic regulation. The primary factors driving this market include the urgent requirement for non-invasive treatment alternatives that boost patient compliance and the rapidly escalating global burden of metabolic conditions. As reported by the International Diabetes Federation in 2024, roughly 589 million adults globally were living with diabetes, generating substantial demand for these sophisticated therapeutic interventions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 23.86 Billion
Market Size 2031USD 36.31 Billion
CAGR 2026-20317.25%
Fastest Growing SegmentCGM Systems
Largest MarketNorth America

However, a major obstacle hindering market progression is the prohibitive expense associated with these advanced biologics and devices, which restricts access in cost-conscious regions and creates significant reimbursement difficulties. This economic hurdle, coupled with rigorous regulatory standards for approving complex combination products, limits the pace at which these therapies become available to the broader patient population.

Market Driver

The rising global prevalence of diabetes and obesity-related comorbidities acts as a major catalyst accelerating the adoption of integrated delivery systems and advanced pharmacological interventions. This surge in metabolic disorders drives patient dependence on next-generation therapies, specifically dual GIP and GLP-1 receptor agonists, which deliver superior glycemic control and weight management compared to conventional insulin regimens. A direct correlation exists between increasing disease incidence and the commercial success of these novel biologics, as healthcare providers prioritize treatments that address both glucose regulation and weight reduction. Reflecting this high demand, Eli Lilly and Company reported in their Q2 2024 financial results that worldwide revenue for the therapy Mounjaro jumped to $3.09 billion in the second quarter alone, highlighting the role of disease burden in driving the uptake of innovative formulations.

Furthermore, rapid advancements in closed-loop and automated insulin delivery systems stimulate market growth by meeting the growing patient need for continuous, minimally invasive monitoring solutions. Technologies merging real-time data analytics with automated dosing alleviate the cognitive load on patients and lower hypoglycemia risks associated with manual injections. The proliferation of these sophisticated devices is crucial for managing the wider metabolic crisis, particularly given the World Health Organization's 2024 report that over 1 billion people worldwide were living with obesity, creating a vast need for scalable therapeutic options. Consequently, manufacturers are seeing strong adoption; Abbott's Third Quarter 2024 financial results indicated global sales of the FreeStyle Libre system reached $1.6 billion, driven by its ability to facilitate personalized care.

Market Challenge

The high cost associated with advanced diabetes biologics and devices represents a significant barrier that directly hampers the growth of the Global Next Generation Diabetes Therapy and Drug Delivery Market. Although automated delivery systems and novel insulin analogs provide superior glycemic control, their elevated price points make them inaccessible to a large portion of the global population, especially in developing regions where out-of-pocket payment is common. This economic disparity limits the addressable market primarily to affluent demographics or those with extensive insurance coverage, making it difficult for manufacturers to scale adoption rates outside of developed markets.

Moreover, this financial burden leads to intensified scrutiny from insurance providers and healthcare payers, resulting in strict reimbursement criteria that delay market penetration. The immense scale of existing costs makes payers reluctant to approve expensive new therapies. According to the International Diabetes Federation, diabetes accounted for an estimated USD 1.015 trillion in global health expenditure in 2024. This profound financial strain compels healthcare systems to prioritize cost containment, thereby restricting the widespread funding and uptake of premium therapeutic technologies.

Market Trends

The market is witnessing a distinct shift toward miniaturized and tubeless wearable patch pump technologies, which are fundamentally transforming insulin delivery mechanisms. In contrast to traditional durable pumps that rely on tubing, these discreet, waterproof devices adhere directly to the skin, offering patients increased freedom and minimizing the stigma often associated with visible medical equipment. This specific form factor is particularly appealing to younger demographics and individuals with active lifestyles who previously avoided pump therapy due to the physical limitations of tubed devices. The commercial viability of this trend is evident in Insulet Corporation's Third Quarter 2024 financial results, where revenue hit $543.9 million, largely driven by high demand for their tubeless automated insulin delivery platform.

Concurrently, there is a rapid expansion of open-architecture diabetes ecosystems and device interoperability, facilitating the seamless integration of components from various manufacturers. This trend moves away from proprietary, single-brand systems, allowing patients to pair their preferred insulin pumps with different continuous glucose monitoring sensors to create customized management solutions. This flexibility improves user experience and promotes broader adoption of automated therapy by eliminating hardware compatibility barriers that formerly restricted patient choice. Reflecting the financial impact of this cross-compatibility strategy, Tandem Diabetes Care reported in their Third Quarter 2024 financial results that worldwide sales totaled $243.5 million, bolstered by the integration of their pump platforms with multiple sensor technologies.

Key Market Players

  • Abbott Laboratories
  • Dexcom Inc.
  • Eli Lilly and Company
  • Enteris BioPharma Inc.
  • GlySens Incorporated
  • MannKind Corporation
  • Medtronic plc
  • Sanofi S.A.
  • Senseonics, Holdings

Report Scope

In this report, the Global Next Generation Diabetes Therapy and Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next Generation Diabetes Therapy and Drug Delivery Market, By Product Type

  • Inhalable Insulin
  • Oral Insulin
  • Insulin Patches
  • CGM Systems
  • Artificial Pancreas

Next Generation Diabetes Therapy and Drug Delivery Market, By Indication

  • Type 1 diabetes
  • Type 2 diabetes

Next Generation Diabetes Therapy and Drug Delivery Market, By End user

  • Diagnostic/Clinics
  • Intensive Care Units (ICUs)
  • Home Healthcare

Next Generation Diabetes Therapy and Drug Delivery Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Diabetes Therapy and Drug Delivery Market.

Available Customizations:

Global Next Generation Diabetes Therapy and Drug Delivery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Next Generation Diabetes Therapy and Drug Delivery Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas)
    • 5.2.2. By Indication (Type 1 diabetes, Type 2 diabetes)
    • 5.2.3. By End user (Diagnostic/Clinics, Intensive Care Units (ICUs), Home Healthcare)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Next Generation Diabetes Therapy and Drug Delivery Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Indication
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By End user
    • 6.3.2. Canada Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By End user
    • 6.3.3. Mexico Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By End user

7. Europe Next Generation Diabetes Therapy and Drug Delivery Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Indication
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By End user
    • 7.3.2. France Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By End user
    • 7.3.3. United Kingdom Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By End user
    • 7.3.4. Italy Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By End user
    • 7.3.5. Spain Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By End user

8. Asia Pacific Next Generation Diabetes Therapy and Drug Delivery Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Indication
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End user
    • 8.3.2. India Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End user
    • 8.3.3. Japan Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End user
    • 8.3.4. South Korea Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By End user
    • 8.3.5. Australia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By End user

9. Middle East & Africa Next Generation Diabetes Therapy and Drug Delivery Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Indication
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End user
    • 9.3.2. UAE Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End user
    • 9.3.3. South Africa Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End user

10. South America Next Generation Diabetes Therapy and Drug Delivery Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Indication
    • 10.2.3. By End user
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By End user
    • 10.3.2. Colombia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By End user
    • 10.3.3. Argentina Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Next Generation Diabetes Therapy and Drug Delivery Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Dexcom Inc.
  • 15.3. Eli Lilly and Company
  • 15.4. Enteris BioPharma Inc.
  • 15.5. GlySens Incorporated
  • 15.6. MannKind Corporation
  • 15.7. Medtronic plc
  • 15.8. Sanofi S.A.
  • 15.9. Senseonics, Holdings

16. Strategic Recommendations

17. About Us & Disclaimer